Frontlight ResearchEarly access
Taking peoplePhase 2
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Key facts
- Who runs it
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 75 people, planned
- Started
- 31 Dec 2025
- Expected to end
- Sept 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- SHR-2173 injection
- Record updated
- 26 January 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age 18-75 years, regardless of gender
- Weight ≥40.0 kg at screening
- Diagnosed as primary membranous nephropathy through kidney biopsy
Who cannot take part
- Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation
- Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period
- Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period
- Subjects who have a malignant tumor or a history of malignant tumor
- Secondary membranous nephropathy
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
The 3 groups in the trial
- Treatment group ATreatment being tested
Treatment: SHR-2173 injection
- Treatment group BTreatment being tested
Treatment: SHR-2173 injection
- Treatment group CTreatment being tested
Treatment: SHR-2173 injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07289763, who can take part
- Record updated
- 26 January 2026